Literature DB >> 11107075

Frequency of postoperative carotid duplex surveillance and type of closure: results from a randomized trial.

A F AbuRahma1, P A Robinson, D A Mullins, S M Holt, T A Herzog, N T Mowery.   

Abstract

BACKGROUND/
PURPOSE: In several nonrandomized studies investigators have reported on the value of postoperative carotid duplex surveillance (PCDS) with mixed results; however the type of closure was not analyzed in these studies. In this study we analyze the frequency and timing of postoperative carotid duplex ultrasound scanning according to the type of closure from a randomized carotid endarterectomy (CEA) trial comparing primary closure (PC) versus patching. PATIENT POPULATION AND METHODS: We randomized 399 CEAs into 135 PCs, 134 polytetrafluoroethylene (PTFE) patch closures, and 130 vein patch closures (VPCs) with a mean follow-up of 47 months. PCDS was done at 1, 6, and 12 months and every year thereafter (a mean of 4.0 studies per artery). Kaplan-Meier analysis was used to estimate the rate of > or = 80% restenosis over time and the time frame of progression from < 50%, to 50%-79% and > or = 80% stenosis.
RESULTS: Restenoses of > or =80% developed in 24 (21%) arteries with PC and nine (4%) with patching. Kaplan-Meier estimate of freedom of > or = 80% restenosis at 1, 2, 3, 4, and 5 years was 92%, 83%, 80%, 76%, and 68% for PC, respectively, and 100%, 99%, 98%, 98%, and 91% for patching, respectively, (P <.01). Of 56 arteries with 20% to 50% restenosis, two of 28 patch closures and 10 of 28 PCs progressed to 50% to < 80% restenosis (P =.02); none of the patch closures and six of 28 PCs progressed to > or =80% (P =.03). In PCs, the median time to progression from <50% to 50%-79%, < 50% to > or =80%, and 50%-79% to > or = 80% was 42, 46, and 7 months, respectively. Of the 24 arteries with > or =80% restenosis in PC, 10 were symptomatic. Thus, assuming th symptomatic restenosis would have undergone duplex scan examinations regardless, there were 14 asymptomatic arteries (12%) that could have been detected only with PCDS (estimated cost, $139, 200), and those patients would have been candidates for redo CEA. Of the 9 arteries (3 PTFE closures and 6 VPCs) with > or =80% restenosis with patch closures, 6 asymptomatic (4 VPCs and 2 PTFE closures) arteries (3%) could have been detected with PCDS. In patients with normal duplex scan findings at the first 6 months, only four (2%) of 222 patched arteries (two asymptomatic) developed > or = 80% restenosis versus five (38%) of 13 in patients with abnormal duplex scan examination findings (P<.001).
CONCLUSIONS: PCDS is beneficial in patients with PC, but is less beneficial in patients with patch closure. PCDS examinations at 6 months and at 1- to 2-year intervals for several years after PC are adequate. For patients with patching, a 6-month postoperative duplex scan examination with normal results is adequate.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11107075     DOI: 10.1067/mva.2000.111281

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  3 in total

1.  The value and economic analysis of routine postoperative carotid duplex ultrasound surveillance after carotid endarterectomy.

Authors:  Ali F AbuRahma; Mohit Srivastava; Zachary AbuRahma; Will Jackson; Albeir Mousa; Patrick A Stone; L Scott Dean; Jason Green
Journal:  J Vasc Surg       Date:  2015-05-09       Impact factor: 4.268

Review 2.  Patch angioplasty versus primary closure for carotid endarterectomy.

Authors:  Saritphat Orrapin; Thoetphum Benyakorn; Boonying Siribumrungwong; Kittipan Rerkasem
Journal:  Cochrane Database Syst Rev       Date:  2022-08-03

Review 3.  Carotid endarterectomy with patch angioplasty versus primary closure in patients with symptomatic and significant stenosis: a systematic review with meta-analyses and trial sequential analysis of randomized clinical trials.

Authors:  Martijn S Marsman; Jørn Wetterslev; Abdelkarime Kh Jahrome; Christian Gluud; Frans L Moll; Frederik Keus; Giel G Koning
Journal:  Syst Rev       Date:  2021-05-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.